These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 11368130)

  • 41. Comparison of fluoxetine, bupropion, and placebo in the treatment of premenstrual dysphoric disorder.
    Pearlstein TB; Stone AB; Lund SA; Scheft H; Zlotnick C; Brown WA
    J Clin Psychopharmacol; 1997 Aug; 17(4):261-6. PubMed ID: 9241004
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Fluoxetine's spectrum of action in premenstrual syndrome.
    Menkes DB; Taghavi E; Mason PA; Howard RC
    Int Clin Psychopharmacol; 1993; 8(2):95-102. PubMed ID: 8345163
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Fluoxetine versus Vitex agnus castus extract in the treatment of premenstrual dysphoric disorder.
    Atmaca M; Kumru S; Tezcan E
    Hum Psychopharmacol; 2003 Apr; 18(3):191-5. PubMed ID: 12672170
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Fluoxetine in the treatment of late luteal phase dysphoric disorder.
    Stone AB; Pearlstein TB; Brown WA
    J Clin Psychiatry; 1991 Jul; 52(7):290-3. PubMed ID: 2071558
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A pilot study to compare fluoxetine, calcium, and placebo in the treatment of premenstrual syndrome.
    Yonkers KA; Pearlstein TB; Gotman N
    J Clin Psychopharmacol; 2013 Oct; 33(5):614-20. PubMed ID: 23963058
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Luteal phase administration of agents for the treatment of premenstrual dysphoric disorder.
    Freeman EW
    CNS Drugs; 2004; 18(7):453-68. PubMed ID: 15139800
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Escitalopram administered in the luteal phase exerts a marked and dose-dependent effect in premenstrual dysphoric disorder.
    Eriksson E; Ekman A; Sinclair S; Sörvik K; Ysander C; Mattson UB; Nissbrandt H
    J Clin Psychopharmacol; 2008 Apr; 28(2):195-202. PubMed ID: 18344730
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Treatment of premenstrual dysphoric disorder with the GABA
    Bixo M; Ekberg K; Poromaa IS; Hirschberg AL; Jonasson AF; Andréen L; Timby E; Wulff M; Ehrenborg A; Bäckström T
    Psychoneuroendocrinology; 2017 Jun; 80():46-55. PubMed ID: 28319848
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Fluoxetine in the treatment of premenstrual dysphoria.
    Su TP; Schmidt PJ; Danaceau MA; Tobin MB; Rosenstein DL; Murphy DL; Rubinow DR
    Neuropsychopharmacology; 1997 May; 16(5):346-56. PubMed ID: 9109106
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Premenstrual syndrome and premenstrual dysphoric disorder.
    Biggs WS; Demuth RH
    Am Fam Physician; 2011 Oct; 84(8):918-24. PubMed ID: 22010771
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Symptom-onset dosing with citalopram in the treatment of premenstrual dysphoric disorder (PMDD): a case series.
    Ravindran LN; Woods SA; Steiner M; Ravindran AV
    Arch Womens Ment Health; 2007; 10(3):125-7. PubMed ID: 17431739
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Medical (fluoxetine) and psychological (cognitive-behavioural therapy) treatment for premenstrual dysphoric disorder: a study of treatment processes.
    Hunter MS; Ussher JM; Cariss M; Browne S; Jelley R; Katz M
    J Psychosom Res; 2002 Sep; 53(3):811-7. PubMed ID: 12217456
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Differential time course efficacy on dysphoric and physical symptoms of the intermittent dosing of fluoxetine in the premenstrual dysphoric disorder.
    Tamayo JM; Gómez G; Barrios R; Holguín J; Adrianzén C
    J Clin Psychopharmacol; 2004 Aug; 24(4):469-71. PubMed ID: 15232351
    [No Abstract]   [Full Text] [Related]  

  • 54. Psychosocial functioning in women with premenstrual dysphoric disorder before and after treatment with sertraline or placebo.
    Pearlstein TB; Halbreich U; Batzar ED; Brown CS; Endicott J; Frank E; Freeman EW; Harrison WM; Haskett RF; Stout AL; Yonkers KA
    J Clin Psychiatry; 2000 Feb; 61(2):101-9. PubMed ID: 10732657
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Assessment of sexual drive and desire in women with premenstrual dysphoric disorder who have been treated with fluoxetine.
    Steiner M; MacDougall M; Berger C; Carter D; Reid R; Steinberg S; Stewart D
    Int J Psychiatry Clin Pract; 2005; 9(2):120-3. PubMed ID: 24930793
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Selective serotonin reuptake inhibitors and treatment of premenstrual dysphoric disorder.
    Finfgeld DL
    Perspect Psychiatr Care; 2002; 38(2):50-60. PubMed ID: 12132631
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Intermittent selective serotonin reuptake inhibitors for premenstrual syndromes: A systematic review and meta-analysis of randomised trials.
    Reilly TJ; Wallman P; Clark I; Knox CL; Craig MC; Taylor D
    J Psychopharmacol; 2023 Mar; 37(3):261-267. PubMed ID: 35686687
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The efficacy of Hypericum perforatum (St John's wort) for the treatment of premenstrual syndrome: a randomized, double-blind, placebo-controlled trial.
    Canning S; Waterman M; Orsi N; Ayres J; Simpson N; Dye L
    CNS Drugs; 2010 Mar; 24(3):207-25. PubMed ID: 20155996
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Non-contraceptive oestrogen-containing preparations for controlling symptoms of premenstrual syndrome.
    Naheed B; Kuiper JH; Uthman OA; O'Mahony F; O'Brien PM
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD010503. PubMed ID: 28257559
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Treating premenstrual dysphoric disorder using serotonin agents.
    Lin J; Thompson DS
    J Womens Health Gend Based Med; 2001 Oct; 10(8):745-50. PubMed ID: 11703886
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.